P. Jumes

发表

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin

S. Xu, M. Rizk, Pratik Bhagunde, 2019, British journal of clinical pharmacology.

Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects.

J. Wagner, P. Jumes, J. Schwartz, 2011, Cardiovascular therapeutics.

Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct‐Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse‐Transcriptase Inhibitor Tenofovir Disoproxil Fumarate

P. Jumes, J. Butterton, D. Panebianco, 2019, Clinical pharmacology in drug development.

Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir

P. Jumes, J. Butterton, D. Panebianco, 2018, The Journal of antimicrobial chemotherapy.

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects

M. Rizk, P. Jumes, Elizabeth G. Rhee, 2018, Antimicrobial Agents and Chemotherapy.

Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa

P. Jumes, R. Gould, G. Hartman, 1999 .

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

D. Rader, S. Previs, B. Hubbard, 2017, Arteriosclerosis, thrombosis, and vascular biology.

Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid‐1 Receptor (CB1R) Inverse Agonist

J. Chodakewitz, J. Wagner, P. Jumes, 2009, Journal of clinical pharmacology.

Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa.

P. Jumes, R. Gould, G. Hartman, 1999, Blood.

Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir

A. Howe, P. Jumes, S. Black, 2015, Antimicrobial Agents and Chemotherapy.

Susceptibilities of Genotype 1 a , 1 b , and 3 Hepatitis C Virus Variants to the NS 5 A Inhibitor Elbasvir

A. Howe, P. Jumes, S. Black, 2015 .

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

M. Rizk, Francheska M. Colón-González, Yang Liu, 2018, Antimicrobial Agents and Chemotherapy.

Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry.

Michael E. Lassman, D. Rader, M. Cleary, 2013, Rapid communications in mass spectrometry : RCM.

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E[S]

Michael E. Lassman, D. Rader, H. Ginsberg, 2017, Journal of Lipid Research.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, The Journal of clinical investigation.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Michael E. Lassman, D. Rader, H. Ginsberg, 2015, The Journal of clinical investigation.

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein

Michael E. Lassman, D. Rader, H. Ginsberg, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers

X. Chu, P. Jumes, J. Butterton, 2019, Antimicrobial Agents and Chemotherapy.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy

L. Webster, P. Jumes, J. Butterton, 2018, Clinical and translational science.

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

J. Chodakewitz, W. Kraft, J. Wagner, 2010, Platelets.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy

L. Webster, P. Jumes, J. Butterton, 2018, Clinical and translational science.

Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.

R. Nachbar, A. Hüser, E. Gane, 2018, Clinical therapeutics.

Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure

S. Zeuzem, H. Wedemeyer, E. Gane, 2017, Hepatology.

Pharmacokinetic Interactions Between the HCV Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, or Darunavir in Healthy Participants

X. Chu, P. Jumes, J. Butterton, 2019 .

Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)

R. Dagan, P. Jumes, Maria Hemming-Harlo, 2022, Vaccine.